Achilles tendinopathy: mixed or unspecified location · Review · 2026
Does shockwave help long-lasting Achilles pain more than sham treatment?
In this review of 8 trials with 458 adults, pain and function with shockwave ended close to sham at 1, 3 and 6 months. People who had symptoms for less than a year may have had a little more early pain relief; that finding needs confirming.
Similar to sham overall- randomised trials
- 8
- adults with long-lasting Achilles pain
- 458
- compared with
- Placebo
Good to know: Trials used radial or focused shockwave, mostly 3 to 4 sessions.
Ni T, Zhao Y, Pang L, et al. PeerJ, 2026 · Read the paper ↗
How this study worked
Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.
What happened
- trials with 1-month pain results
- 6
- people
- 348
- Compared with
- Sham shockwave; in most trials both groups also had the same exercise or advice
Pain: shockwave compared with sham
Difference in pain change, 0–10 scale
Show the numbers
| Difference (points on a 0–10 pain scale) | likely range | |
|---|---|---|
| Pain at 1 month | −0.39 | −0.85 to 0.08 |
| Pain at 3 months | −0.56 | −1.4 to 0.28 |
What the trials used
- ESWT modalities and dose range
- Four studies radial, three focused, one combined; reported protocols used about 1,500–4,500 shocks/session over mostly three to four sessions. Intensities ranged 0.1–0.6 mJ/mm² or 1.5–5 bar as source-reported; do not convert between units.
- Sham and co-interventions
- Sham methods included zero energy, disconnected probes, air cavities or interposed material to attenuate waves while reproducing device cues. Seven studies matched exercise, stretching or education across arms; protocols varied.
Who took part
Eight RCTs included 458 adults with chronic Achilles tendinopathy. Outcome-specific pooled samples differed by endpoint/time; the source reports these in Table 4, with some malformed patient/study count cells for AOFAS.
Side effects
Mild side effects in 7 of 156 people with shockwave and 2 of 162 with sham; none needed treatment.
All the numbers and the full appraisal
Every reported result
The results, in numbers.
Eight RCTs included 458 adults with chronic Achilles tendinopathy. Outcome-specific pooled samples differed by endpoint/time; the source reports these in Table 4, with some malformed patient/study count cells for AOFAS.
Pain change (ΔVAS)6 reported outcomes
Pain change (ΔVAS)
Visual Analog Scale (0–10) WMD points in change score
ESWT versus sham ESWT
6 studies · 348 participants in this estimate · 0%
Reported estimate and confidence interval.
No statistically significant pooled between-group difference was reported.
Analysis details and source
I²=0%; source-reported pooled change-score estimate.
Pain change (ΔVAS)
Visual Analog Scale (0–10) WMD points in change score
ESWT versus sham ESWT
6 studies · 323 participants in this estimate · 64%
Reported estimate and confidence interval.
No statistically significant pooled between-group difference was reported.
Analysis details and source
I²=64%; source-reported pooled change-score estimate.
Pain change (ΔVAS)
Visual Analog Scale (0–10) WMD points in change score
ESWT versus sham ESWT
2 studies · 127 participants in this estimate · 0%
Reported estimate and confidence interval.
No statistically significant pooled between-group difference was reported.
Analysis details and source
I²=0%; source-reported pooled change-score estimate.
Pain change (ΔVAS)
Visual Analog Scale (0–10) WMD points in change score
ESWT versus sham ESWT
2 studies · 93 participants in this estimate · 0%
Reported estimate and confidence interval.
No statistically significant pooled between-group difference was reported.
Analysis details and source
I²=0%; source-reported pooled change-score estimate.
Pain change with symptom duration <12 months, 1 month
Visual Analog Scale (0–10) WMD points in change score
ESWT versus sham among participants with symptoms <12 months
4 studies · 173 participants in this estimate · 0%
Reported estimate and confidence interval.
Exploratory subgroup difference favored ESWT but was smaller than the review-stated VAS MCID of 1.1 points; this hypothesis-generating result requires confirmation.
Analysis details and source
Prespecified symptom-duration subgroup per Methods, but explicitly treated as hypothesis-generating; do not generalize to the overall population.
Pain change with symptom duration <12 months, 3 months
Visual Analog Scale (0–10) WMD points in change score
ESWT versus sham among participants with symptoms <12 months
3 studies · 119 participants in this estimate · 0%
Reported estimate and confidence interval.
Exploratory subgroup difference favored ESWT and exceeded the review-stated VAS MCID of 1.1 points; this hypothesis-generating result requires confirmation.
Analysis details and source
Prespecified symptom-duration subgroup per Methods, but explicitly treated as hypothesis-generating; do not generalize to the overall population.
Function change (ΔVISA-A)3 reported outcomes
Function change (ΔVISA-A)
Victorian Institute of Sports Assessment–Achilles (VISA-A) WMD points in change score
ESWT versus sham ESWT
3 studies · 219 participants in this estimate · 72%
Reported estimate and confidence interval.
No statistically significant pooled between-group difference was reported.
Analysis details and source
I²=72%; source-reported pooled change-score estimate. Values are as printed in Tables 4–6 (WMD 3.26, 95% CI −0.98 to 7.49, P = 0.13); the Results text reports WMD 2.79 (95% CI −5.27 to 10.86; I² = 72%; P = 0.50) for the same three-study comparison. Neither shows a significant difference.
Function change (ΔVISA-A)
Victorian Institute of Sports Assessment–Achilles (VISA-A) WMD points in change score
ESWT versus sham ESWT
2 studies · 154 participants in this estimate · 37%
Reported estimate and confidence interval.
No statistically significant pooled between-group difference was reported.
Analysis details and source
I²=37%; source-reported pooled change-score estimate.
Function change (ΔVISA-A)
Victorian Institute of Sports Assessment–Achilles (VISA-A) WMD points in change score
ESWT versus sham ESWT
2 studies · 138 participants in this estimate · 0%
Reported estimate and confidence interval.
No statistically significant pooled between-group difference was reported.
Analysis details and source
I²=0%; source-reported pooled change-score estimate.
Function change (ΔAOFAS)3 reported outcomes
Function change (ΔAOFAS)
American Orthopaedic Foot and Ankle Society (AOFAS) score WMD points in change score
ESWT versus sham ESWT
4 studies · 0%
Reported estimate and confidence interval.
The source reports no significant difference. Table 4 prints the number of studies/patients in reversed or malformed order for AOFAS; participant count is therefore left null.
Analysis details and source
I²=0%; source-reported pooled change-score estimate.
Function change (ΔAOFAS)
American Orthopaedic Foot and Ankle Society (AOFAS) score WMD points in change score
ESWT versus sham ESWT
3 studies · 82%
Reported estimate and confidence interval.
The source reports no significant difference. Table 4 prints the number of studies/patients in reversed or malformed order for AOFAS; participant count is therefore left null.
Analysis details and source
I²=82%; source-reported pooled change-score estimate.
Function change (ΔAOFAS)
American Orthopaedic Foot and Ankle Society (AOFAS) score WMD points in change score
ESWT versus sham ESWT
2 studies · 0%
Reported estimate and confidence interval.
The source reports no significant difference. Table 4 prints the number of studies/patients in reversed or malformed order for AOFAS; participant count is therefore left null.
Analysis details and source
I²=0%; source-reported pooled change-score estimate.
Study-reported adverse events1 reported outcome
Participants with adverse events
Study-reported adverse events Odds ratio
ESWT versus sham
5 studies · 318 participants in this estimate · 35%
Reported estimate and confidence interval. Logarithmic ratio scale.
Seven of 156 ESWT participants and two of 162 sham participants had mild adverse events; the pooled difference was not statistically significant.
Analysis details and source
Reported events were mild and required no specific intervention. Participant count 318 is directly represented by the source arm denominators 156 and 162.
VAS pain change by modality: rESWT5 reported outcomes
VAS pain change by modality: rESWT
VAS pain change weighted mean difference, score points
rESWT versus sham/control ESWT
5 studies · 305 participants in this estimate · I²=0%
Reported estimate and confidence interval.
Modality subgroup estimate: −0.37 (95% CI -0.89 to 0.14; p=0.15; I²=0%). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.
VAS pain change by modality: rESWT + fESWT
VAS pain change weighted mean difference, score points
rESWT + fESWT versus sham/control ESWT
1 study · 43 participants in this estimate · I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: −0.45 (95% CI -1.45 to 0.64; p=0.42; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.
VAS pain change by modality: rESWT
VAS pain change weighted mean difference, score points
rESWT versus sham/control ESWT
I²=68%
Reported estimate and confidence interval.
Modality subgroup estimate: −0.24 (95% CI -1.28 to 0.81; p=0.65; I²=68%). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.
VAS pain change by modality: fESWT
VAS pain change weighted mean difference, score points
fESWT versus sham/control ESWT
1 study · 49 participants in this estimate · I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: −1.57 (95% CI -3.4 to 0.26; p=0.09; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.
VAS pain change by modality: rESWT + fESWT
VAS pain change weighted mean difference, score points
rESWT + fESWT versus sham/control ESWT
1 study · 43 participants in this estimate · I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: −1.15 (95% CI -2.3 to 0.02; p=0.06; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.
VISA-A function change by modality: rESWT4 reported outcomes
VISA-A function change by modality: rESWT
VISA-A function change weighted mean difference, scale points
rESWT versus sham/control ESWT
2 studies · 177 participants in this estimate · I²=80%
Reported estimate and confidence interval.
Modality subgroup estimate: 0.22 (95% CI -11.54 to 11.97; p=0.97; I²=80%). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.
VISA-A function change by modality: fESWT
VISA-A function change weighted mean difference, scale points
fESWT versus sham/control ESWT
1 study · 42 participants in this estimate · I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: 6.37 (95% CI -1.22 to 10.26; p=0.12; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control. As printed (Table 4, fESWT row; also Table 5, Mixed row): the estimate 6.37 is not at the centre of its printed 95% CI (−1.22 to 10.26; centre 4.52), so one of these printed numbers is probably a misprint.
VISA-A function change by modality: rESWT
VISA-A function change weighted mean difference, scale points
rESWT versus sham/control ESWT
1 study · 96 participants in this estimate · I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: −2.40 (95% CI -12.26 to 7.46; p=0.63; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.
VISA-A function change by modality: fESWT
VISA-A function change weighted mean difference, scale points
fESWT versus sham/control ESWT
1 study · 42 participants in this estimate · I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: 3.40 (95% CI -3.46 to 10.26; p=0.33; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The source contribution count is transcribed as shown. The source comparison is against sham ESWT/control.
AOFAS function change by modality: rESWT7 reported outcomes
AOFAS function change by modality: rESWT
AOFAS function change weighted mean difference, scale points
rESWT versus sham/control ESWT
I²=50%
Reported estimate and confidence interval.
Modality subgroup estimate: 1.99 (95% CI -3.48 to 7.46; p=0.48; I²=50%). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.
AOFAS function change by modality: fESWT
AOFAS function change weighted mean difference, scale points
fESWT versus sham/control ESWT
I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: 3.20 (95% CI -2.27 to 8.67; p=0.25; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.
AOFAS function change by modality: rESWT + fESWT
AOFAS function change weighted mean difference, scale points
rESWT + fESWT versus sham/control ESWT
I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: 2.30 (95% CI -4.52 to 9.12; p=0.51; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.
AOFAS function change by modality: rESWT
AOFAS function change weighted mean difference, scale points
rESWT versus sham/control ESWT
I²=90%
Reported estimate and confidence interval.
Modality subgroup estimate: 3.34 (95% CI -11.46 to 18.14; p=0.66; I²=90%). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.
AOFAS function change by modality: rESWT + fESWT
AOFAS function change weighted mean difference, scale points
rESWT + fESWT versus sham/control ESWT
I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: 4.99 (95% CI -1.84 to 11.82; p=0.15; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.
AOFAS function change by modality: rESWT
AOFAS function change weighted mean difference, scale points
rESWT versus sham/control ESWT
I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: −1.70 (95% CI -8 to 4.6; p=0.60; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.
AOFAS function change by modality: fESWT
AOFAS function change weighted mean difference, scale points
fESWT versus sham/control ESWT
I²=NA
Reported estimate and confidence interval.
Modality subgroup estimate: 1.70 (95% CI -4.89 to 8.29; p=0.61; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.
Adverse events by modality: rESWT3 reported outcomes
Adverse events by modality: rESWT
Adverse events odds ratio
rESWT versus sham/control ESWT
I²=61%
Reported estimate and confidence interval. Logarithmic ratio scale.
Modality subgroup estimate: 2.06 (95% CI 0.09 to 46.09; p=0.65; I²=61%). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.
Adverse events by modality: fESWT
Adverse events odds ratio
fESWT versus sham/control ESWT
I²=NA
Reported estimate and confidence interval. Logarithmic ratio scale.
Modality subgroup estimate: 6.71 (95% CI 0.31 to 147.37; p=0.23; I²=NA). This exploratory result does not establish a treatment-modality interaction.
Analysis details and source
Exploratory Table 4 subgroup. The printed study/patient contribution cell is malformed; counts are left null. The source comparison is against sham ESWT/control.
Adverse events by modality: rESWT + fESWT
Adverse events odds ratio
Table 4 reports the radial-plus-focused ESWT adverse-event subgroup as not estimable (43 participants, one study).
Analysis details and source
The source marks the estimate and interval as not estimable; no comparative effect is inferred.
VAS in diagnosis tendinopathy: insertional16 reported outcomes
VAS in diagnosis tendinopathy: insertional
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: insertional
3 studies · 208 participants in this estimate · I²=16%
Reported estimate and confidence interval.
VAS diagnosis subgroup at 1 month: -0.2 (95% CI -0.82 to 0.41; p=.52; I²=16%).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in diagnosis tendinopathy: non-insertional
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: non-insertional
1 study · 50 participants in this estimate · I²=NA
Reported estimate and confidence interval.
VAS diagnosis subgroup at 1 month: -0.9 (95% CI -2.36 to 0.56; p=.23; I²=NA).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in diagnosis tendinopathy: mixed
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: mixed
2 studies · 90 participants in this estimate · I²=0%
Reported estimate and confidence interval.
VAS diagnosis subgroup at 1 month: -0.56 (95% CI -1.38 to 0.26; p=.18; I²=0%).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in diagnosis tendinopathy: insertional
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: insertional
I²=0%
Reported estimate and confidence interval.
VAS diagnosis subgroup at 3 month: 0.35 (95% CI -0.31 to 1; p=.30; I²=0%). The source prints contribution cell “186 (3)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
VAS in diagnosis tendinopathy: mixed
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: mixed
I²=0%
Reported estimate and confidence interval.
VAS diagnosis subgroup at 3 month: -1.37 (95% CI -2.11 to 0.63; p=.08; I²=0%). The source prints contribution cell “137 (3)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null. As printed in Table 5: the estimate −1.37 is not at the centre of its printed 95% CI (−2.11 to 0.63; centre −0.74), so one of these printed numbers is probably a misprint.
VAS in diagnosis tendinopathy: insertional
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: insertional
2 studies · 127 participants in this estimate · I²=0%
Reported estimate and confidence interval.
VAS diagnosis subgroup at 6 month: 0.14 (95% CI -0.71 to 1; p=.74; I²=0%).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in diagnosis tendinopathy: non-insertional
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: non-insertional
1 study · 50 participants in this estimate · I²=NA
Reported estimate and confidence interval.
VAS diagnosis subgroup at >6 months: -0.5 (95% CI -2.02 to 1.02; p=.52; I²=NA).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in diagnosis tendinopathy: mixed
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: mixed
1 study · 43 participants in this estimate · I²=NA
Reported estimate and confidence interval.
VAS diagnosis subgroup at >6 months: -0.77 (95% CI -2.61 to 1.07; p=.41; I²=NA).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in symptom duration tendinopathy: <12 months
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: <12 months
4 studies · 173 participants in this estimate · I²=0%
Reported estimate and confidence interval.
VAS symptom-duration subgroup at 1 month: -0.76 (95% CI -1.42 to -0.09; p=.03; I²=0%).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in symptom duration tendinopathy: ≥12 months
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: ≥12 months
2 studies · 177 participants in this estimate · I²=0%
Reported estimate and confidence interval.
VAS symptom-duration subgroup at 1 month: -0.03 (95% CI -0.68 to 0.62; p=.93; I²=0%).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in symptom duration tendinopathy: <12 months
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: <12 months
3 studies · 119 participants in this estimate · I²=0%
Reported estimate and confidence interval.
VAS symptom-duration subgroup at 3 month: -1.23 (95% CI -1.97 to -0.5; p=.001; I²=0%).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in symptom duration tendinopathy: ≥12 months
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: ≥12 months
3 studies · 204 participants in this estimate · I²=55%
Reported estimate and confidence interval.
VAS symptom-duration subgroup at 3 month: 0.09 (95% CI -0.95 to 1.12; p=.87; I²=55%).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in symptom duration tendinopathy: <12 months
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: <12 months
1 study · 31 participants in this estimate · I²=NA
Reported estimate and confidence interval.
VAS symptom-duration subgroup at 6 month: 0 (95% CI -1.92 to 1.92; p=1.00; I²=NA).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in symptom duration tendinopathy: ≥12 months
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: ≥12 months
1 study · 96 participants in this estimate · I²=NA
Reported estimate and confidence interval.
VAS symptom-duration subgroup at 6 month: 0.18 (95% CI -0.77 to 1.13; p=.71; I²=NA).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in symptom duration tendinopathy: <12 months
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: <12 months
1 study · 50 participants in this estimate · I²=NA
Reported estimate and confidence interval.
VAS symptom-duration subgroup at >6 months: -0.5 (95% CI -2.02 to 1.02; p=.52; I²=NA).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VAS in symptom duration tendinopathy: ≥12 months
VAS weighted mean difference, VAS points
ESWT versus sham; subgroup: ≥12 months
1 study · 43 participants in this estimate · I²=NA
Reported estimate and confidence interval.
VAS symptom-duration subgroup at >6 months: -0.77 (95% CI -2.61 to 1.07; p=.41; I²=NA).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VISA-A in diagnosis tendinopathy: insertional8 reported outcomes
VISA-A in diagnosis tendinopathy: insertional
VISA-A weighted mean difference, score points
ESWT versus sham; subgroup: insertional
2 studies · 177 participants in this estimate · I²=80%
Reported estimate and confidence interval.
VISA-A diagnosis subgroup at 1 month: 0.22 (95% CI -11.54 to 11.97; p=.97; I²=80%).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VISA-A in diagnosis tendinopathy: mixed
VISA-A weighted mean difference, score points
ESWT versus sham; subgroup: mixed
1 study · 42 participants in this estimate · I²=NA
Reported estimate and confidence interval.
VISA-A diagnosis subgroup at 1 month: 6.37 (95% CI -1.22 to 10.26; p=.12; I²=NA).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. As printed (Table 5, Mixed row; also Table 4, fESWT row): the estimate 6.37 is not at the centre of its printed 95% CI (−1.22 to 10.26; centre 4.52), so one of these printed numbers is probably a misprint.
VISA-A in diagnosis tendinopathy: insertional
VISA-A weighted mean difference, score points
ESWT versus sham; subgroup: insertional
2 studies · 154 participants in this estimate · I²=37%
Reported estimate and confidence interval.
VISA-A diagnosis subgroup at 3 month: 3.9 (95% CI -1.4 to 9.19; p=.15; I²=37%).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VISA-A in diagnosis tendinopathy: insertional
VISA-A weighted mean difference, score points
ESWT versus sham; subgroup: insertional
1 study · 96 participants in this estimate · I²=NA
Reported estimate and confidence interval.
VISA-A diagnosis subgroup at 6 month: -2.4 (95% CI -12.26 to 7.46; p=.63; I²=NA).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VISA-A in diagnosis tendinopathy: mixed
VISA-A weighted mean difference, score points
ESWT versus sham; subgroup: mixed
1 study · 42 participants in this estimate · I²=NA
Reported estimate and confidence interval.
VISA-A diagnosis subgroup at 6 month: 3.4 (95% CI -3.46 to 10.26; p=.33; I²=NA).
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VISA-A in symptom duration tendinopathy: ≥12 months
VISA-A weighted mean difference, score points
ESWT versus sham; subgroup: ≥12 months
3 studies · 219 participants in this estimate · I²=72%
Reported estimate and confidence interval.
VISA-A symptom-duration subgroup at 1 month: 3.26 (95% CI -0.98 to 7.49; p=.13; I²=72%).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. This row repeats the overall three-study estimate; the Results text reports WMD 2.79 (95% CI −5.27 to 10.86; P = 0.50) for that comparison instead.
VISA-A in symptom duration tendinopathy: ≥12 months
VISA-A weighted mean difference, score points
ESWT versus sham; subgroup: ≥12 months
2 studies · 154 participants in this estimate · I²=37%
Reported estimate and confidence interval.
VISA-A symptom-duration subgroup at 3 month: 3.9 (95% CI -1.4 to 9.19; p=.15; I²=37%).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
VISA-A in symptom duration tendinopathy: ≥12 months
VISA-A weighted mean difference, score points
ESWT versus sham; subgroup: ≥12 months
2 studies · 138 participants in this estimate · I²=0%
Reported estimate and confidence interval.
VISA-A symptom-duration subgroup at 6 month: 1.51 (95% CI -4.13 to 7.14; p=.60; I²=0%).
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence.
AOFAS in diagnosis tendinopathy: insertional11 reported outcomes
AOFAS in diagnosis tendinopathy: insertional
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: insertional
I²=NA
Reported estimate and confidence interval.
AOFAS diagnosis subgroup at 1 month: -0.6 (95% CI -5.65 to 4.45; p=.82; I²=NA). The source prints contribution cell “108 (1)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
AOFAS in diagnosis tendinopathy: mixed
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: mixed
I²=0%
Reported estimate and confidence interval.
AOFAS diagnosis subgroup at 1 month: 3.49 (95% CI -0.27 to 7.05; p=.07; I²=0%). The source prints contribution cell “132 (3)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
AOFAS in diagnosis tendinopathy: insertional
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: insertional
I²=NA
Reported estimate and confidence interval.
AOFAS diagnosis subgroup at 3 month: -4.1 (95% CI -10.08 to 1.88; p=.18; I²=NA). The source prints contribution cell “82 (1)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
AOFAS in diagnosis tendinopathy: mixed
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: mixed
I²=31%
Reported estimate and confidence interval.
AOFAS diagnosis subgroup at 3 month: 3.96 (95% CI -2.14 to 7.85; p=.08; I²=31%). The source prints contribution cell “88 (2)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null. As printed (Table 5, Mixed row; also Table 6, <12 months row): the estimate 3.96 is not at the centre of its printed 95% CI (−2.14 to 7.85; centre about 2.86), so one of these printed numbers is probably a misprint.
AOFAS in diagnosis tendinopathy: insertional
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: insertional
I²=NA
Reported estimate and confidence interval.
AOFAS diagnosis subgroup at 6 month: -1.7 (95% CI -8 to 4.6; p=.60; I²=NA). The source prints contribution cell “96 (1)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
AOFAS in diagnosis tendinopathy: mixed
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: mixed
I²=NA
Reported estimate and confidence interval.
AOFAS diagnosis subgroup at 6 month: 1.7 (95% CI -4.89 to 8.29; p=.61; I²=NA). The source prints contribution cell “42 (1)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
AOFAS in symptom duration tendinopathy: <12 months
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: <12 months
I²=0%
Reported estimate and confidence interval.
AOFAS symptom-duration subgroup at 1 month: 3.85 (95% CI -0.61 to 8.3; p=.09; I²=0%). The source prints contribution cell “90 (2)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
AOFAS in symptom duration tendinopathy: ≥12 months
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: ≥12 months
I²=0%
Reported estimate and confidence interval.
AOFAS symptom-duration subgroup at 1 month: 1.15 (95% CI -2.56 to 4.86; p=.54; I²=0%). The source prints contribution cell “150 (2)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
AOFAS in symptom duration tendinopathy: <12 months
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: <12 months
I²=31%
Reported estimate and confidence interval.
AOFAS symptom-duration subgroup at 3 month: 3.96 (95% CI -2.14 to 7.85; p=.08; I²=31%). The source prints contribution cell “88 (2)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null. As printed (Table 6, <12 months row; also Table 5, Mixed row): the estimate 3.96 is not at the centre of its printed 95% CI (−2.14 to 7.85; centre about 2.86), so one of these printed numbers is probably a misprint.
AOFAS in symptom duration tendinopathy: ≥12 months
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: ≥12 months
I²=NA
Reported estimate and confidence interval.
AOFAS symptom-duration subgroup at 3 month: -4.1 (95% CI -10.08 to 1.88; p=.18; I²=NA). The source prints contribution cell “82 (1)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
AOFAS in symptom duration tendinopathy: ≥12 months
AOFAS weighted mean difference, score points
ESWT versus sham; subgroup: ≥12 months
I²=0%
Reported estimate and confidence interval.
AOFAS symptom-duration subgroup at 6 month: -0.08 (95% CI -4.63 to 4.48; p=.97; I²=0%). The source prints contribution cell “138 (2)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
adverse-events in diagnosis tendinopathy: insertional4 reported outcomes
adverse-events in diagnosis tendinopathy: insertional
adverse-events odds ratio
ESWT versus sham; subgroup: insertional
I²=61%
Reported estimate and confidence interval. Logarithmic ratio scale.
adverse-events diagnosis subgroup during follow-up as reported: 2.06 (95% CI 0.09 to 46.09; p=.65; I²=61%). The source prints contribution cell “226 (3)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
adverse-events in diagnosis tendinopathy: mixed
adverse-events odds ratio
ESWT versus sham; subgroup: mixed
I²=NA
Reported estimate and confidence interval. Logarithmic ratio scale.
adverse-events diagnosis subgroup during follow-up as reported: 6.71 (95% CI 0.31 to 147.37; p=.23; I²=NA). The source prints contribution cell “92 (2)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 5 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
adverse-events in symptom duration tendinopathy: <12 months
adverse-events odds ratio
ESWT versus sham; subgroup: <12 months
I²=NA
Reported estimate and confidence interval. Logarithmic ratio scale.
adverse-events symptom-duration subgroup during follow-up as reported: 11.16 (95% CI 0.55 to 227.6; p=.12; I²=NA). The source prints contribution cell “74 (2)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
adverse-events in symptom duration tendinopathy: ≥12 months
adverse-events odds ratio
ESWT versus sham; subgroup: ≥12 months
I²=42%
Reported estimate and confidence interval. Logarithmic ratio scale.
adverse-events symptom-duration subgroup during follow-up as reported: 1.52 (95% CI 0.12 to 19.73; p=.75; I²=42%). The source prints contribution cell “244 (3)”; study and participant counts are not assigned because the cell is malformed.
Analysis details and source
Exploratory, hypothesis-generating Table 6 subgroup; do not treat subgroup patterns as established effect modification. Nonsignificance is not equivalence. Malformed contribution cell preserved; counts left null.
How treatment was delivered
Four studies radial, three focused, one combined; reported protocols used about 1,500–4,500 shocks/session over mostly three to four sessions. Intensities ranged 0.1–0.6 mJ/mm² or 1.5–5 bar as source-reported; do not convert between units.
Sham methods included zero energy, disconnected probes, air cavities or interposed material to attenuate waves while reproducing device cues. Seven studies matched exercise, stretching or education across arms; protocols varied.
Five RCTs reported mild adverse events: 7/156 ESWT participants (4.5%) versus 2/162 sham participants (1.2%). Events did not require specific medical intervention; pooled OR 2.89 (95% CI 0.75–11.04; p=.12), with no statistically significant difference.
The review included only eight trials and outcome-level participant totals were modest. The authors rated primary findings low to moderate certainty; modality and disease-subtype subgroup analyses were constrained.
Raw XML Tables 4–6 contain malformed or apparently reversed study/patient count cells for some AOFAS and subgroup rows. Those participant counts are not used unless clearly reported in prose or unambiguous cells. The linked supplementary raw data were unavailable.
All significant symptom-duration results are exploratory subgroup findings, including one below the stated MCID. They do not override null overall pooled comparisons.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- The review included only eight trials and outcome-level participant totals were modest. The authors rated primary findings low to moderate certainty; modality and disease-subtype subgroup analyses were constrained.
- Raw XML Tables 4–6 contain malformed or apparently reversed study/patient count cells for some AOFAS and subgroup rows. Those participant counts are not used unless clearly reported in prose or unambiguous cells. The linked supplementary raw data were unavailable.
- All significant symptom-duration results are exploratory subgroup findings, including one below the stated MCID. They do not override null overall pooled comparisons.
Source-linked critical reading
Systematic review with meta-analysis
Technical source record
Complete full-text XML read with all six raw tables and figure captions inspected; results and each section of discussion/conclusions read. Three linked supplements were not part of retrieved XML.
This review found no clear overall advantage of shockwave therapy over sham for chronic Achilles pain or function. A possible short-term signal in people with symptoms under 12 months comes from exploratory subgroup analyses and needs confirmation.
For adults with chronic Achilles tendinopathy, does ESWT improve pain or function compared with sham ESWT, and what harms are reported?
PRISMA systematic review and meta-analysis of randomized sham-controlled trials. Searches covered four databases through February 20, 2025; eight RCTs were included. Primary outcomes were changes in VAS, VISA-A and AOFAS.
Eight trials included 458 participants with chronic Achilles tendinopathy (symptoms ≥3 months), including insertional, non-insertional and mixed presentations. The review reports study-level totals; outcome-specific pooled samples vary by timepoint.
Four studies used radial ESWT, three focused ESWT and one combined modalities. Protocols varied in device, intensity, shocks and schedules; most delivered three or four sessions. Seven trials also provided balanced exercise/education co-interventions.
ESWT was compared with sham designed to mimic the procedure while attenuating or eliminating pressure waves. Co-interventions were generally matched within each trial.
Across follow-ups, pooled mean differences in change scores were nonsignificant for VAS, VISA-A and AOFAS. At 1, 3, 6 and >6 months, VAS WMDs were −0.39, −0.56, 0.14 and −0.61; all CIs included no difference. VISA-A at 1, 3 and 6 months and AOFAS at 1, 3 and 6 months were also nonsignificant.
Primary pooled estimates did not show ESWT superiority over sham. Exploratory subgroup analyses found lower VAS change scores for symptoms <12 months at 1 month (WMD −0.76, 95% CI −1.42 to −0.09) and 3 months (−1.23, −1.97 to −0.50); authors flag these as hypothesis-generating, and only the 3-month estimate exceeded the stated 1.1-point VAS MCID.
Five studies reported mild events not requiring specific treatment. Events occurred in 7/156 ESWT participants (4.5%) and 2/162 sham participants (1.2%); pooled OR 2.89 (95% CI 0.75–11.04; p=.12), not statistically significant.
Eight trials and modest outcome-specific samples limited precision. Protocols, devices, co-interventions and populations varied; secondary reporting includes malformed Table 4/5 cells where study and participant counts appear reversed or inconsistent. Publication bias was not formally assessed because fewer than ten studies contributed. Subgroups are exploratory.
The sham comparison estimates the specific incremental effect of ESWT beyond procedure context and shared co-care. Overall findings do not establish added pain or functional benefit. The early-symptom subgroup signal is uncertain and cannot guide treatment alone.
Future sham-controlled trials should standardize diagnosis, ESWT parameters and matched loading programs, report complete outcome-level denominators and confidence intervals, monitor adverse events, and prospectively power prespecified symptom-duration analyses.
Read the original article.
Extracorporeal shockwave therapy versus sham extracorporeal shockwave therapy for chronic Achilles tendinopathy: a meta-analysis of randomized controlled trials.
Ni T, Zhao Y, Pang L, Fu W. · PeerJ · 2026
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →